MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$16,784K
Free Cash flow
-$32,522K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Maturities of marketable securit...
    • Proceeds from issuance of pre-fu...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Repurchase of common stock, incl...
    • Prepaid expenses and other asset...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-45,637
-33,685
-25,559
-26,130
Depreciation expense
260
274
272
280
Accretion income on marketable securities
340
292
424
337
Stock-based compensation expense
12,368
3,824
3,282
3,688
Other non-cash items
19
0
0
0
Non-cash lease expense
423
412
402
392
Prepaid expenses and other assets
1,417
-1,727
-2,683
1,534
Other long-term assets
622
46
194
92
Accounts payable
-326
1,024
-430
602
Accrued expenses and other liabilities
3,168
-2,745
-124
3,345
Operating lease liabilities
-397
-386
-377
-358
Net cash used in operating activities
-32,501
-29,893
-20,469
-20,144
Purchases of property and equipment
21
102
176
45
Purchases of marketable securities
256,014
-
0
73,974
Maturities of marketable securities
30,000
55,000
30,000
30,000
Net cash provided by (used in) investing activities
-226,035
54,898
29,824
-44,019
Proceeds from exercise of stock options
80
56
0
1,008
Proceeds from exercise of warrants
0
123
-
-
Proceeds from issuance of common stock from follow-on offering, net of issuance costs
259,384
-
0
0
Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs
21,381
-
0
0
Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs
0
-
0
0
Proceeds from issuance of common stock under atm facility, net of issuance costs
-
-
2,767
3,287
Repurchase of common stock, including transaction costs
39,093
-
-
-
Proceeds from espp purchases
0
121
0
68
Net cash provided by financing activities
241,752
300
2,767
4,363
Net increase in cash, cash equivalents and restricted cash
-16,784
25,305
12,122
-59,800
Effect of exchange rate changes on cash and cash equivalents
-173
-27
-160
-26
Cash, cash equivalents and restricted cash at beginning of period
85,561
60,283
48,321
32,461
Cash, cash equivalents and restricted cash at end of period
68,604
85,561
60,283
48,321
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock from...$259,384K (457.61%↑ Y/Y)Proceeds from issuance ofpre-funded warrants from...$21,381K (51.04%↑ Y/Y)Proceeds from exercise ofstock options$80K (3900.00%↑ Y/Y)Net cash provided byfinancing activities$241,752K (245.24%↑ Y/Y)Canceled cashflow$39,093K Net increase incash, cash...-$16,784K (-122.18%↓ Y/Y)Canceled cashflow$241,752K Maturities of marketablesecurities$30,000K (-50.00%↓ Y/Y)Stock-based compensationexpense$12,368K (68.34%↑ Y/Y)Accrued expenses andother liabilities$3,168K (248.13%↑ Y/Y)Non-cash lease expense$423K (-44.12%↓ Y/Y)Depreciation expense$260K (-54.94%↓ Y/Y)Other non-cash items$19K (-29.63%↓ Y/Y)Repurchase of common stock,including transaction...$39,093K Net cash provided by(used in) investing...-$226,035K (-553.98%↓ Y/Y)Canceled cashflow$30,000K Net cash used inoperating activities-$32,501K (26.35%↑ Y/Y)Canceled cashflow$16,238K Purchases of marketablesecurities$256,014K (2464.24%↑ Y/Y)Purchases of property andequipment$21K (-90.71%↓ Y/Y)Net loss-$45,637K (16.27%↑ Y/Y)Prepaid expenses andother assets$1,417K (149.17%↑ Y/Y)Other long-termassets$622K (286.79%↑ Y/Y)Operating leaseliabilities-$397K (39.57%↑ Y/Y)Accretion income onmarketable securities$340K (-56.69%↓ Y/Y)Accounts payable-$326K (67.98%↑ Y/Y)

Aura Biosciences, Inc. (AURA)

Aura Biosciences, Inc. (AURA)